FDA Reviews Cetirizine And PPIs For Potential Serious Safety Risks
This article was originally published in The Tan Sheet
Executive Summary
Adverse event reports prompt FDA to evaluate potential links between the active ingredient in Zyrtec and oculogyric crisis, and between proton pump inhibitors and pneumonia. The agency points out the investigation does not mean a risk exists, and advises consumers to continue use of the products.